Overview

• Sanofi has entered into a definitive agreement to acquire Vigil Neuroscience for $8 per share in cash, with an additional $2 per share contingent on VG-3927's first commercial sale.
• The deal, valued at up to $600 million, strengthens Sanofi's neurology portfolio by adding VG-3927, an oral TREM2 agonist targeting Alzheimer's disease.
• VG-3927 aims to enhance the neuroprotective function of microglia, addressing critical unmet needs in Alzheimer’s treatment.
• The acquisition is expected to close in Q3 2025, subject to regulatory and shareholder approvals, as well as other customary conditions.
• Vigil’s other program, VGL101, is excluded from the deal and will return to its original licensor, Amgen, prior to the transaction’s completion.